Bio-Techne TECH Change in net unrealized gain (loss) on derivative instruments
Change in net unrealized gain (loss) on derivative instruments at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent.
The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Techne's change in net unrealized gain (loss) on derivative instruments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Techne's change in net unrealized gain (loss) on derivative instruments?
- Bio-Techne (TECH) reported change in net unrealized gain (loss) on derivative instruments of -$160K in Q1 2026.
- How has Bio-Techne's change in net unrealized gain (loss) on derivative instruments changed year-over-year?
- Bio-Techne's change in net unrealized gain (loss) on derivative instruments increased by 90.7% year-over-year, from -$1.71M to -$160K.
- What is the long-term trend for Bio-Techne's change in net unrealized gain (loss) on derivative instruments?
- Over 3 years (2022 to 2025), Bio-Techne's change in net unrealized gain (loss) on derivative instruments has grown at a -26.9% compound annual growth rate (CAGR), from $14.26M to -$5.57M.
- What does change in net unrealized gain (loss) on derivative instruments mean?
- This metric tracks the change in the fair value of derivative instruments designated as cash flow hedges that are not yet recognized in net income. It reflects the unrealized gains or losses on financial instruments used to mitigate risks such as interest rate or foreign currency fluctuations.